Business Wire

VA-REGULA

7.3.2024 08:01:27 CET | Business Wire | Press release

Share
Regula Elevates ID Fraud Protection with Enhanced Liveness Checks

Liveness detection, both for individuals and their IDs, has become a cornerstone for a secure customer onboarding process. It is especially crucial in remote scenarios where document submission and verification are done via the Internet. With 65% of organizations globally relying on digital document checks in their online identity verification workflows, robust anti-fraud measures cannot be overrated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240306499292/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Regula Document Reader SDK verifies the authenticity of an ID by checking its optically variable features (Photo: Business Wire)

Responding to this growing need for additional fraud protection, Regula has released an update for its Regula Document Reader SDK, a comprehensive solution for the most reliable and secure identity document verification. Thanks to improved neural networks, detecting and analyzing an identity document has become twice as fast. The software is now able to check dynamic security features that were previously eligible for verification in on-site scenarios only. These checks include, but are not limited to:

  • Optically Variable Ink (OVI), which changes color depending on the angle of observation and illumination;
  • Lenticular images, such as Multiple Laser Image (MLI) and Dynaprint, which consist of several initial images that appear depending on the angle of observation;
  • Holograms, which reflect and form an image in reflected light when changing the angle of observation and illumination.

The updated Regula Document Reader SDK can reliably validate the authenticity of an ID by verifying such optically variable features. The solution employs advanced algorithms to analyze the presence of these features and images in documents, as well as their exact location, their content, and their liveness—e.g., changing colors, images, etc.—based on a specific document template. All a user needs to do is show their ID in front of a smartphone camera, and the rest is technology. With advanced document liveness detection, Regula Document Reader SDK effectively prevents identity fraud and other types of fraud, such as printed photo attacks and screen replay attacks.

Apart from that, all the client-side data retrieved during liveness checks and verification sessions can be securely transferred in encrypted form to the backend client’s server. Captured document images, session video, RFID session data, document liveness session data, and other processing data can be used to re-process a verification session in a customer’s trusted environment. This “zero-trust-to-mobile” approach adds an important layer of trustworthiness to the verification process, as it ensures that no data is manipulated by fraudsters while being transferred from mobile devices.

“Today, a mere $15 is all it takes to get an AI-generated ID — a golden ticket to illicit banking and crypto operations, and to circumventing anti-money laundering protocols. Amid this digital wild west, the necessity for document liveness checks has never been more critical. They serve as an essential counter-fraud measure, preventing identity theft and document tampering. By ensuring that a real document is being presented during onboarding, you can significantly enhance the verification process to prove that it is genuine and not a counterfeit or digital replica. That’s why we never stop researching and improving the functionality of Regula Document Reader SDK,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about the recent update of Regula Document Reader SDK, please visit the official webpage.

About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.

Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.

Learn more at regulaforensics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240306499292/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release

Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and

Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release

Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit

Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse

Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig

PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release

Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli

Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release

Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye